CN113906013B - 吡啶氮氧化合物及其制备方法和用途 - Google Patents

吡啶氮氧化合物及其制备方法和用途 Download PDF

Info

Publication number
CN113906013B
CN113906013B CN202080037787.2A CN202080037787A CN113906013B CN 113906013 B CN113906013 B CN 113906013B CN 202080037787 A CN202080037787 A CN 202080037787A CN 113906013 B CN113906013 B CN 113906013B
Authority
CN
China
Prior art keywords
alkyl
compound
pharmaceutically acceptable
pain
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080037787.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN113906013A (zh
Inventor
张琼
王中利
戴明
程凤凯
罗九
叶艳
彭建彪
郭海兵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jiyu Pharmaceutical Technology Co Ltd
Original Assignee
Shanghai Jiyu Pharmaceutical Technology Co ltd
Jiangxi Jemincare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jiyu Pharmaceutical Technology Co ltd, Jiangxi Jemincare Group Co Ltd filed Critical Shanghai Jiyu Pharmaceutical Technology Co ltd
Priority to CN202410255352.5A priority Critical patent/CN118146148A/zh
Publication of CN113906013A publication Critical patent/CN113906013A/zh
Application granted granted Critical
Publication of CN113906013B publication Critical patent/CN113906013B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN202080037787.2A 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途 Active CN113906013B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410255352.5A CN118146148A (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201910863718 2019-09-12
CN2019108637186 2019-09-12
CN201911094782 2019-11-11
CN2019110947829 2019-11-11
CN202010531381 2020-06-11
CN2020105313811 2020-06-11
CN2020109233110 2020-09-04
CN202010923311 2020-09-04
PCT/CN2020/114700 WO2021047622A1 (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410255352.5A Division CN118146148A (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN113906013A CN113906013A (zh) 2022-01-07
CN113906013B true CN113906013B (zh) 2024-03-12

Family

ID=74866555

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202080037787.2A Active CN113906013B (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途
CN202010957957.0A Active CN112479996B (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途
CN202410255352.5A Pending CN118146148A (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202010957957.0A Active CN112479996B (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途
CN202410255352.5A Pending CN118146148A (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途

Country Status (17)

Country Link
US (1) US20230303495A9 (cg-RX-API-DMAC10.html)
EP (1) EP4043437A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022548104A (cg-RX-API-DMAC10.html)
KR (1) KR20220101606A (cg-RX-API-DMAC10.html)
CN (3) CN113906013B (cg-RX-API-DMAC10.html)
AU (1) AU2020346951A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022004495A8 (cg-RX-API-DMAC10.html)
CA (1) CA3150400A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022000619A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022004594A2 (cg-RX-API-DMAC10.html)
GE (2) GEP20247688B (cg-RX-API-DMAC10.html)
MX (1) MX2022003032A (cg-RX-API-DMAC10.html)
PE (1) PE20221515A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022550584A1 (cg-RX-API-DMAC10.html)
TW (1) TWI770607B (cg-RX-API-DMAC10.html)
WO (1) WO2021047622A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202204100B (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024509939A (ja) * 2021-03-11 2024-03-05 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド ピリジン窒素酸化物の結晶形態およびその使用
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
SMT202600064T1 (it) 2021-06-04 2026-03-09 Vertex Pharma Forme farmaceutiche solide e regimi di dosaggio comprendenti (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metossi-fenil)-4,5-dimetil-5-(trifluorometil) tetraidrofuran-2-carbonil]ammino]piridin-2-carbossammide
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
CA3221939A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
US20240368135A1 (en) 2021-06-04 2024-11-07 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
CN116891432A (zh) * 2022-04-02 2023-10-17 武汉人福创新药物研发中心有限公司 Nav1.8抑制剂及其用途
IL316422A (en) 2022-04-22 2024-12-01 Vertex Pharma Heteroaryl compounds for pain treatment
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
EP4534529A4 (en) * 2022-06-02 2026-06-03 Shanghai Jemincare Pharmaceuticals Co Ltd PROCESS FOR PREPARING A PYRIDINE OXYNITRIDIDE COMPOUND
TW202413335A (zh) * 2022-06-22 2024-04-01 大陸商武漢人福創新藥物研發中心有限公司 Ｎａｖ１．８抑制劑
KR20250120351A (ko) 2022-12-06 2025-08-08 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법
TW202434235A (zh) * 2023-01-18 2024-09-01 芬蘭商奧利安公司 ３－（４，５－二氯－２－（４－（三氟甲氧基）苯氧基）苯甲醯胺基）吡啶１－氧化物的製備方法
CN121419965A (zh) * 2023-06-14 2026-01-27 上海济煜医药科技股份有限公司 吡啶氮氧化合物的盐型、共晶及其制备方法和应用
WO2024255833A1 (zh) * 2023-06-14 2024-12-19 上海济煜医药科技有限公司 吡啶氮氧化合物与富马酸的共晶体及其组合物、用途和制备方法
KR20260116140A (ko) 2023-10-23 2026-07-28 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물
KR20260116141A (ko) 2023-10-23 2026-07-28 버텍스 파마슈티칼스 인코포레이티드 통증 치료용 화합물 및 이의 고체 형태의 제조방법
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
KR20260118418A (ko) 2023-10-23 2026-07-30 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물
AU2024393245A1 (en) 2023-12-07 2026-06-18 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
WO2025124502A1 (zh) * 2023-12-13 2025-06-19 武汉人福创新药物研发中心有限公司 一种Nav1.8抑制剂化合物及其盐、多晶型和用途
TW202606663A (zh) 2024-06-28 2026-02-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
LU605402B1 (en) 2024-07-11 2026-07-14 Sea4Us Biotecnologia E Recursos Marinhos Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075465A1 (ja) * 2006-12-19 2008-06-26 Mitsui Chemicals, Inc. 植物種子用又は収穫物用殺虫組成物およびその使用方法
CN101466665A (zh) * 2006-04-11 2009-06-24 沃泰克斯药物股份有限公司 适用作电压-门控钠通道抑制剂的组合物
CN101855210A (zh) * 2007-10-11 2010-10-06 沃泰克斯药物股份有限公司 用作电压-门控钠通道抑制剂的酰胺类
CN101883758A (zh) * 2007-10-11 2010-11-10 沃泰克斯药物股份有限公司 用作电压门控的钠通道抑制剂的芳基酰胺类化合物
CN105026373A (zh) * 2013-01-31 2015-11-04 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
CN105073738A (zh) * 2013-01-31 2015-11-18 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹唑啉酰胺类
CN105814067A (zh) * 2013-12-13 2016-07-27 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺的前药
WO2019014352A1 (en) * 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS
WO2020014246A1 (en) * 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834468A (en) * 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
BRPI0611596A2 (pt) * 2005-06-21 2010-09-21 Mitsui Chemicals Inc derivado de amina e inseticida contendo o mesmo
US9656959B2 (en) * 2010-12-22 2017-05-23 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
BR112015018284B1 (pt) * 2013-01-31 2023-03-07 Vertex Pharmaceuticals Incorporated Amidas como moduladores de canais de sódio, seus usos, e composição farmacêutica

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466665A (zh) * 2006-04-11 2009-06-24 沃泰克斯药物股份有限公司 适用作电压-门控钠通道抑制剂的组合物
WO2008075465A1 (ja) * 2006-12-19 2008-06-26 Mitsui Chemicals, Inc. 植物種子用又は収穫物用殺虫組成物およびその使用方法
CN101855210A (zh) * 2007-10-11 2010-10-06 沃泰克斯药物股份有限公司 用作电压-门控钠通道抑制剂的酰胺类
CN101883758A (zh) * 2007-10-11 2010-11-10 沃泰克斯药物股份有限公司 用作电压门控的钠通道抑制剂的芳基酰胺类化合物
CN105026373A (zh) * 2013-01-31 2015-11-04 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
CN105073738A (zh) * 2013-01-31 2015-11-18 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹唑啉酰胺类
CN105814067A (zh) * 2013-12-13 2016-07-27 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺的前药
WO2019014352A1 (en) * 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS
WO2020014246A1 (en) * 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cobalt-Catalyzed Direct C-H Thiolation of Aromatic Amides with Disulfides: Application to the Synthesis of Quetiapine;Mingliang Li, et al.;《Org. Lett.》;20181004;第20卷;第6490-6493页 *
Copper-Mediated Direct Aryloxylation of Benzamides Assisted by an N,O-Bidentate Directing Group;Xin-Qi Hao et al.;《Org. Lett.》;20140206;第16卷;第1104-1107页 *
Cu(II)-Mediated Ortho-C-H Amination of Arenes with Free Amines;Manoj Kumar, et al.;《J. Org. Chem.》;20190522;第84卷;第8067-8079页 *
Yi Jiang, et al..Brønsted Base-Switched Selective Mono- and Dithiolation of Benzamides via Copper Catalysis.《J. Org. Chem.》.2019,第84卷第10490-10500页. *

Also Published As

Publication number Publication date
BR112022004495A2 (pt) 2022-05-31
EP4043437A4 (en) 2023-10-04
CN112479996A (zh) 2021-03-12
US20230303495A9 (en) 2023-09-28
CN118146148A (zh) 2024-06-07
GEP20247688B (en) 2024-11-11
CN113906013A (zh) 2022-01-07
US20230026907A1 (en) 2023-01-26
TW202114990A (zh) 2021-04-16
CA3150400A1 (en) 2021-03-18
CL2022000619A1 (es) 2022-10-28
EP4043437A1 (en) 2022-08-17
CO2022004594A2 (es) 2022-07-08
GEAP202415928A (en) 2024-07-10
ZA202204100B (en) 2024-04-24
CN112479996B (zh) 2023-05-26
JP2022548104A (ja) 2022-11-16
MX2022003032A (es) 2022-07-12
PH12022550584A1 (en) 2024-03-04
WO2021047622A1 (zh) 2021-03-18
BR112022004495A8 (pt) 2023-04-18
AU2020346951A1 (en) 2022-04-28
KR20220101606A (ko) 2022-07-19
TWI770607B (zh) 2022-07-11
PE20221515A1 (es) 2022-10-04

Similar Documents

Publication Publication Date Title
CN112479996B (zh) 吡啶氮氧化合物及其制备方法和用途
CN112225695B (zh) 一种氮氧化合物及其制备方法和用途
JP2022548104A5 (cg-RX-API-DMAC10.html)
US12246008B2 (en) 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels
US20220380338A1 (en) Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
US11292799B2 (en) Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
US20210188808A1 (en) Compounds as neuronal histamine receptor-3 antagonists and uses thereof
US11299497B2 (en) Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
US20240400547A1 (en) 2,6-piperidinedione compound and application thereof
US11981681B2 (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
EP3283487B1 (en) Pyridopyrimidinones and their use as nmda receptor modulators
US20190023684A1 (en) Substituted 5-cyanoindole compounds and uses thereof
KR20240019064A (ko) 피리딘 질소 산화물 화합물의 결정 형태 및 이의 용도
JP2023554673A (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）阻害剤としての三環式ピリミジン
KR20220106778A (ko) 간 x 수용체 작용제로서의 1,2,4-옥사디아졸 유도체
HK40061625A (en) Pyridine oxynitride, preparation method therefor and use thereof
HK40061625B (en) Pyridine oxynitride, preparation method therefor and use thereof
WO2019037791A1 (zh) 一种长效雷沙吉兰前药及其制备方法和用途
HK40041147A (en) Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
HK40041147B (en) Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40061625

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250402

Address after: 201315, 1st Floor, No. 2, Lane 535, Huanqiao Road, Pudong New Area, Shanghai

Patentee after: Shanghai Jiyu Pharmaceutical Technology Co.,Ltd.

Country or region after: China

Address before: 201203 1st floor, building 1, No. 1118, Halley Road, Pudong New Area pilot Free Trade Zone, Shanghai

Patentee before: Shanghai Jiyu Pharmaceutical Technology Co.,Ltd.

Country or region before: China

Patentee before: JIANGXI JEMINCARE GROUP Co.,Ltd.

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 201315, 1st Floor, No. 2, Lane 535, Huanqiao Road, Pudong New Area, Shanghai

Patentee after: Shanghai Jiyu Pharmaceutical Technology Co., Ltd.

Country or region after: China

Address before: 1st Floor, No. 2, Lane 535, Huanqiao Road, Pudong New Area, Shanghai

Patentee before: Shanghai Jiyu Pharmaceutical Technology Co.,Ltd.

Country or region before: China